In vitro Susceptibility of Nontuberculous Mycobacteria to Tedizolid

References

• Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline: executive summary. Clin Infect Dis. 2020;71(4):E1–E36. doi:10.1093/cid/ciaa241
   PubMed Web of Science ®Google Scholar
• Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med. 2012;185(8):881–886. doi:10.1164/rccm.201111-2016OC
   PubMed Web of Science ®Google Scholar
• Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367–416. doi:10.1164/rccm.200604-571ST
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Ku JH, Marras TK, et al. The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease. Eur Respir J. 2015;45(4):1177–1179. doi:10.1183/09031936.00169114
   PubMed Web of Science ®Google Scholar
• Kisgen JJ, Mansour H, Unger NR, Childs LM. Tedizolid: a new oxazolidinone antimicrobial. Am J Health Syst Pharm. 2014;71(8):621–633. doi:10.2146/ajhp130482
   PubMed Web of Science ®Google Scholar
• Burdette SD, Trotman R, Saravolatz LD. Tedizolid: the first once-daily oxazolidinone class antibiotic. Clin Infect Dis. 2015;61(8):1315–1321. doi:10.1093/cid/civ501
   PubMed Web of Science ®Google Scholar
• Rybak JM, Marx K, Martin CA. Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance. Pharmacotherapy. 2014;34(11):1198–1208. doi:10.1002/phar.1491
   PubMed Web of Science ®Google Scholar
• Locke JB, Finn J, Hilgers M, et al. Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the CFR methyltransferase gene or ribosomal mutations. Antimicrob Agents Chemother. 2010;54(12):5337–5343. doi:10.1128/AAC.00663-10
   PubMed Web of Science ®Google Scholar
• Ruiz P, Causse M, Vaquero M, Casal M. In vitro activity of tedizolid against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2019;63(4). doi:10.1128/AAC.01939-18
   Web of Science ®Google Scholar
• Deshpande D, Srivastava S, Pasipanodya JG, Lee PS, Gumbo T. Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease. J Antimicrob Chemother. 2017;72(suppl_2):i30–i35. doi:10.1093/jac/dkx305
   PubMed Web of Science ®Google Scholar
• Flanagan S, McKee EE, Das D, et al. Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function. Antimicrob Agents Chemother. 2015;59(1):178–185. doi:10.1128/AAC.03684-14
   PubMed Web of Science ®Google Scholar
• Yuste JR, Berto J, Del PJ, Leiva J. Prolonged use of tedizolid in a pulmonary non-tuberculous mycobacterial infection after linezolid-induced toxicity. J Antimicrob Chemother. 2017;72(2):625–628. doi:10.1093/jac/dkw484
   PubMed Web of Science ®Google Scholar
• Compain F, Soroka D, Heym B, et al. In vitro activity of tedizolid against the Mycobacterium abscessus complex. Diagn Microbiol Infect Dis. 2018;90(3):186–189. doi:10.1016/j.diagmicrobio.2017.11.001
   Web of Science ®Google Scholar
• Tang YW, Cheng B, Yeoh SF, Lin R, Teo J. Tedizolid activity against clinical Mycobacterium abscessus complex isolates-an in vitro characterization study. Front Microbiol. 2018;9:2095. doi:10.3389/fmicb.2018.02095
   Web of Science ®Google Scholar
• Ruth MM, Koeken V, Pennings LJ, et al. Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease? J Antimicrob Chemother. 2020;75(3):609–617. doi:10.1093/jac/dkz511
   PubMed Web of Science ®Google Scholar
• Le Run E, Arthur M, Mainardi JL. In vitro and intracellular activity of imipenem combined with tedizolid, rifabutin, and avibactam against Mycobacterium abscessus. Antimicrob Agents Chemother. 2019;63(4). doi:10.1128/AAC.01915-18
   PubMed Web of Science ®Google Scholar
• Tortoli E. Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of the 1990s. Clin Microbiol Rev. 2003;16(2):319–354. doi:10.1128/CMR.16.2.319-354.2003
   PubMed Web of Science ®Google Scholar
• Woods GL, Brown-Elliott BA, Conville PS, et al. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes. Wayne (PA): Clinical and Laboratory Standards Institute; 2018.
   Google Scholar
• Zelazny AM, Root JM, Shea YR, et al. Cohort study of molecular identification and typing of Mycobacterium abscessus, Mycobacterium massiliense, and Mycobacterium bolletii. J Clin Microbiol. 2009;47(7):1985-1995. doi:10.1128/JCM.01688-08
   Google Scholar
• Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 2003;52(1):1. doi:10.1093/jac/dkg301
   PubMed Web of Science ®Google Scholar
• Vera-Cabrera L, Brown-Elliott BA, Wallace RJ, et al. In vitro activities of the novel oxazolidinones DA-7867 and DA-7157 against rapidly and slowly growing mycobacteria. Antimicrob Agents Chemother. 2006;50(12):4027–4029. doi:10.1128/AAC.00763-06
   Web of Science ®Google Scholar
• Brown-Elliott BA, Wallace RJ, Land GA. In vitro susceptibility testing of tedizolid against Nontuberculous mycobacteria. J Clin Microbiol. 2017;55(6):1747–1754. doi:10.1128/JCM.00274-17
   PubMed Web of Science ®Google Scholar
• Wen S, Gao X, Zhao W, et al. Comparison of the in vitro activity of linezolid, tedizolid, sutezolid, and delpazolid against rapidly growing mycobacteria isolated in Beijing, China. Int J Infect Dis. 2021;109:253–260. doi:10.1016/j.ijid.2021.06.055
   PubMed Web of Science ®Google Scholar
• Housman ST, Pope JS, Russomanno J, et al. Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers. Antimicrob Agents Chemother. 2012;56(5):2627–2634. doi:10.1128/AAC.05354-11
   PubMed Web of Science ®Google Scholar
• Jaffre J, Aubry A, Maitre T, et al. Rational choice of antibiotics and media for Mycobacterium avium complex drug susceptibility testing. Front Microbiol. 2020;11:81. doi:10.3389/fmicb.2020.00081
   Web of Science ®Google Scholar
• Macheras E, Roux AL, Bastian S, et al. Multilocus sequence analysis and rpoB sequencing of Mycobacterium abscessus (sensu lato) strains. J Clin Microbiol. 2011;49(2):491–499. doi:10.1128/JCM.01274-10
   PubMed Web of Science ®Google Scholar
• Shallom SJ, Gardina PJ, Myers TG, et al. New rapid scheme for distinguishing the subspecies of the Mycobacterium abscessus group and identifying Mycobacterium massiliense isolates with inducible clarithromycin resistance. J Clin Microbiol. 2013;51(9):2943–2949. doi:10.1128/JCM.01132-13
   PubMed Web of Science ®Google Scholar